AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 251 min read$CBLL

Foehr David sold $44K of CBLL

Foehr David (Senior VP, Finance and PAO) sold 1,852 shares of Ceribell, Inc. (CBLL) at an average of $23.99 ($23.95–$24.02) across 2 trades over 2026-08-21 to 2026-08-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Foehr David
Published Aug 25, 2026, 11:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 11:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CBLL
Neutral
high confidence
Mentioned
$CBLL
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CBLLNeutralLow
01

Why it matters

The transaction is a routine insider sell with limited market impact.

02

Market read

Small insider sale; unlikely to move the stock.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 2/10Novelty 3/10Timing: post‑filing 2026‑08‑25

Background

Form 4 filing from Ceribell, Inc. (CBLL) reporting an insider sale under a 10b5‑1 plan.

Company-level read

Ticker impact

$CBLLNeutralHigh confidence
Context

Senior VP of Finance sold 1,852 shares for $44,424.91 via a 10b5‑1 plan, reducing his stake to 35,899 shares.

Expected impact

Likely negligible impact on CBLL price.

Evidence & confidence

The sale size is small relative to market cap and was pre‑arranged, so market reaction is expected to be minimal.

Market effects

Sector

No material effect on the medical‑device sector.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

If the insider is signaling concerns, a modest short could be considered, but evidence is weak.

Key entities

  • company
    Ceribell, Inc.

    NASDAQ‑listed medical‑device firm.

  • insider
    David Foehr

    Senior Vice President, Finance and PAO.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CBLL insider trading history →

Related articles

OCT 2
$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

rttnews.com3 min
SEP 30
$CBLLMedAI 8/10

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

Ceribell, Inc. (Nasdaq: CBLL) received FDA 510(k) clearance for new software for its EEG system, enabling easier interpretation of brain activity trends. The update includes Alpha-Delta Ratio, Burst Suppression, and Amplitude-Integrated EEG monitoring, applicable to patients of all ages. The company expects to roll out the features in the first half of 2027.

globenewswire.com2 min
AUG 10
$CBLLHigh

Ceribell Reports Second Quarter 2026 Financial Results

Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Second Quarter 2026 Financial Results Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor

SEC EDGAR 8-K6 min